Aanbeveling

Het schema van neoadjuvante chemotherapie hangt af van patiënt- en tumorvariabelen en is meestal conform een adjuvant schema.

 

Triple-negatieve tumoren

Bij patiënten met triple-negatieve tumoren (met een HRD-like profiel) verhoogt neoadjuvante chemotherapie met een carboplatin-bevattend schema de kans op een pCR. De toevoeging van carboplatin resulteert in meer toxiciteit.

 

Hormoonreceptor-positieve tumoren

  • Bij patiënten met hormoonreceptor-positieve tumoren is neoadjuvante endocriene therapie een alternatief voor chemotherapie en kan overwogen worden bij oude en fragiele patiënten, of patiënten met een zeer oestrogeengevoelige ziekte (ER > 50%).
  • Indien gekozen wordt voor neoadjuvante endocriene therapie zijn aromataseremmers te verkiezen boven tamoxifen bij postmenopauzale patiënten.

HER2-positieve tumoren

  • Bij de neoadjuvante behandeling van HER2-positieve borstkanker dient trastuzumab toegevoegd te worden aan de neoadjuvante chemotherapie. Het wordt adjuvant tot totaal 1 jaar voortgezet.
  • Bij neoadjuvante behandeling van HER2-positieve borstkanker wordt op grond van de verhoogde kans op een pCR geadviseerd om pertuzumab toe te voegen aan chemotherapie en trastuzumab

Inleiding

Adjuvante systemische therapie na neoadjuvante systemische therapie kan bestaan uit endocriene therapie en/of doelgerichte therapie. Hiervoor gelden dezelfde richtlijnen als bij adjuvante systemische therapie.

Conclusies

Carboplatin bevattende neoadjuvante chemotherapie verhoogt de kans op pCR bij triple negatieve borstkanker.
Niveau 2 B Ando 2014, Sikov 2015
 
Er is in (neo)adjuvante setting geen verschil in effectiviteit van sequentieel 4x driewekelijks AC gevolgd door 12x wekelijks paclitaxel of 4x AC gevolgd door 4x driewekelijks docetaxel dan wel 6x met alle 3 middelen samen (TAC).
Bij triple-negatieve borstkanker bestaat een voorkeur voor 4x AC gevolgd door wekelijks paclitaxel.
Niveau 2 B Vriens 2013, von MG 2005, Bear 2003, Sparano 2017

 

Bij oudere of kwetsbare patiënten met een indicatie voor (neo)adjuvante chemotherapie of bij patiënten met een contra-indicatie voor anthracyclines kan docetaxel/cyclofosfamide (TC) worden overwogen.
Niveau 2 B Jones 2009, Freyer 2011

 

Neoadjuvant gebruik van aromataseremmers is superieur aan neoadjuvant gebruik van tamoxifen bij postmenopauzale patiënten.
Niveau 2 B Charehbili 2014, Leal 2015
 
Bij HER2-positieve tumoren verhoogt het toevoegen van trastuzumab aan chemotherapie de kans op een pathologisch complete respons (pCR).
Niveau 2 B Buzdar 2005, Buzdar2007, Gianni 2010

 

Duale HER2-blokkade middels toevoegen van pertuzumab aan neoadjuvante chemotherapie en trastuzumab bij HER2-positieve tumoren verhoogt de kans op een pCR.
Niveau 2 B Gianni 2010, Gianni 2016
 
Bij residu ziekte na neoadjuvante chemotherapie (geen pCR) geeft adjuvant capecitabine een verbetering bij oestrogeen-receptor-negatieve borstkanker een verbetering van de overleving.
Niveau 2 B Masuda 2017 

Referenties

  1. 1 - Aalders KC, Postma EL, Strobbe LJ, et al. Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. J Clin Oncol. 2016; Jun 20;34(18):2107-14. doi: 10.1200/JCO.2015.64.3536. Epub 2016 Mar 14.
  2. 2 - Aalders KC, van Bommel AC, van Dalen T, et al. Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur J Cancer. 2016; Aug;63:118-26. doi: 10.1016/j.ejca.2016.05.010. Epub 2016 Jun 11.
  3. 3 - Adank MA et al, CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer. Ned Tijdschr Geneeskd. 2015;159:A8910.
  4. 4 - Adank MA et al, Excess breast cancer risk in first degree relatives of CHEK2*1100delC positive familial breast cancer cases. Eur J Cancer. 2013; May ;49(8):1993-9. doi: 10.1016/j.ejca.2013.01.009.
  5. 5 - Adank MA, Jonker MA, Kluijt I, et al. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet. 2011; Dec;48(12):860-3.
  6. 6 - Al-Mubarak M, Tibau A, Templeton AJ, et al. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. PloS one. 2014; 9: e88238. PMC3930532.
  7. 7 - An et al. Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients. Nuklearmedizin. 2014;53(3):89-94.
  8. 8 - Ando M et al, Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat. 2014; Jun;145(2):401-9.
  9. 9 - Antoniou AC et al, Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014; Aug 7;371(6):497-506.
  10. 10 - Bane AL, Whelan TJ, et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Ann Oncol. 2014; May;25(5):992-8.
  11. 11 - Basu NN, Ingham S, et al. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Fam Cancer. 2015; Dec;14(4):531-8. doi: 10.1007/s10689-015-9825-9.
  12. 12 - Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Canceer 2006; 42: 895-904.
  13. 13 - Bear HD, Anderson S, Brown A, et al; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J ClinOncol. 2003; Nov 15;21(22):4165-74.
  14. 14 - Benson JR, Wishart GC. Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. Lancet Oncol. 2013; Aug;14(9):e348-57. doi: 10.1016/S1470-2045(13)70135-9.
  15. 15 - Bernsdorf M, Berthelsen AK, Wielenga VT, et al. Preoperative PET/ CT in early-stage breast cancer. Ann Oncol 2012;23(9):2277–82. http://dx.doi.org/10.1093/annonc/mds002.
  16. 16 - Binkhorst L ea, Augmentation of endoxifen exposure in tamoxifen-treated women following SSRI-switch. Clin Pharmacokinet. 2015; Oct 08; DOI 10.1007/s40262-015-0315-x.
  17. 17 - Blamey RW, Bates T, Chetty U, et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer. 2013; Jul;49(10):2294-302. doi: 10.1016/j.ejca.2013.02.031. Epub 2013 Mar 21.
  18. 18 - Bliss J et al, Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression group. J Nat Cancer Inst. 2007; 99: 516-25.
  19. 19 - Blok E et al, Optimal duration of extended adjuvant endocrine therapy for early breast cancer: results of the IDEAL trial. JNCO. 2017; in press.
  20. 20 - Blok EJ, Derks MG, van der Hoeven JJ, van de Velde CJ, Kroep JR. Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence. Cancer Treat Rev. 2015; Mar;41:271-6
  21. 21 - Boileau JF, Poirier B, Basik M et al. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study. J Clin Oncol. 2015; Jan 20;33(3):258-64. doi: 10.1200/JCO.2014.55.7827. Epub 2014 Dec 1
  22. 22 - Borges S, Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. ClinPharmacolTher. 2006;80:61-74
  23. 23 - Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). Ann Surg. 2016; Apr;263(4):802-7.
  24. 24 - Boughey JC, Suman VJ, Mittendorf EA, et al; Alliance for Clinical Trials in Oncology. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015; Mar;261(3):547-52.
  25. 25 - Boughey, Suman, Mittendorf et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with lymph node-positive breast cancer. The ACOZOG Z1071(Alliance) clinical trial. JAMA. 2013; Oct 9; 310 (14); 1455-61
  26. 26 - Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol 2016; 34: 1-15.
  27. 27 - Buzdar AU. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J ClinOncol 2005;23:3676-85
  28. 28 - Cameron D et al, 11 year´s follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer etc. Lancet. 2017;
  29. 29 - Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.
  30. 30 - Caudle AS, Yang WT, Krishnamurthy S, et al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J ClinOncol. 2016; Apr 1;34(10):1072-8.
  31. 31 - Caudle AS, Yang WT, Mittendorf EA, et al. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015;150(2):137-43.
  32. 32 - Caudle AS, Yu TK, Tucker SL, et al. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012; May 23;14(3):R83.
  33. 33 - Chagpar AB, Killelea BK, Tsangaris TN, et al. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med. 2015; Aug 6;373(6):503-10. doi: 10.1056/NEJMoa1504473. Epub 2015; May 30
  34. 34 - Chai X, Domchek S, Kauff N, et al. RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. J Natl Cancer Inst. 2015; Aug 11;107(9). pii: djv217. doi: 10.1093/jnci/djv217. Print 2015 Sep.
  35. 35 - Chan A, Buyse M, Yao B. Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply. Lancet Oncol. 2016; May;17(5):e176-7.
  36. 36 - Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013; Nov 20;31(33):4222-8.
  37. 37 - Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005; Jun 15;65(12):4971-4.
  38. 38 - Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol 2015; 26: 1533-46.
  39. 39 - Cochet A, Dygai-Cochet I, Riedinger JM, et al. ¹8F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014; Mar;41(3):428-37.
  40. 40 - Coleman R, Body JJ, Aapro M, et al; on behalf of the ESMO Guidelines Working Group: Bone health in cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 2014; 25 (Supplement 3): iii124–iii137.
  41. 41 - Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole(ZO-FAST Study): final 60-month results. Ann Oncol 2013;24:398-405.
  42. 42 - Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04). Cancer Res 2010;70(24 Suppl.): Abstract nr S4-5.
  43. 43 - Coles C, Agarwal R, Ah-See ML, et al. Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003). Eur J Cancer 2016;57:S4
  44. 44 - Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005; May 1;103(9):1778-84.
  45. 45 - Correa C, Harris EE, Leonardi MC, et al. Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol. 2017; Mar - Apr;7(2):73-79. doi: 10.1016/j.prro.2016.09.007. Epub 2016 Sep 17.
  46. 46 - Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-72.
  47. 47 - Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015; Feb 1;33(4):304-11. doi: 10.1200/JCO.2014.57.1414. Epub 2014 Dec 1.
  48. 48 - Cronin PA et al, Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Ann Surg Oncol. 2016; Sep;23(9):2816-24.
  49. 49 - Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011; Jan;12(1):21-9.
  50. 50 - Cybulski C, the Polish Hereditary Breast Cancer Consortium. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015; Jun;16(6):638-44.
  51. 51 - Dall P, Lenzen G Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany. J Geriatr Oncol. 2015; Nov;6(6):462-9
  52. 52 - Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381: 805-16. PMC3596060.
  53. 53 - de Korte MA, EG de Vries et al. (111)Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.Eur J cancer 2007; 14:2046-51
  54. 54 - Dekker TJ, Smit VT, Hooijer GK, et al. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Ann Oncol. 2013; Apr;24(4):931-7.
  55. 55 - Derks MGM et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicenter, open-label, randomized phase 3 trial. Lancet Oncol. 2017; in press
  56. 56 - Desmond A, Kurian AW, Gabree M et al. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncol. 2015; Oct;1(7):943-51. doi: 10.1001/jamaoncol.2015.2690.
  57. 57 - Diego EJ, Soran A, McGuire KP, et al. Localizing high-risk lesions for excisional breast biopsy: a comparison between radioactive seed localization and wire localization. Ann SurgOncol. 2014;21(10):3268-72.
  58. 58 - Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008; 19:2007-11.
  59. 59 - Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; Sep 1;304(9):967-75
  60. 60 - Dominici LC, Negron Gonzalez VM, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 2010; 116(12):2884-9.
  61. 61 - Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015; Feb;261(2):378-82.
  62. 62 - Donker M, van Tienhoven G, Straver M.E, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303-10.
  63. 63 - Donker M, Vrancken Peeters MJ, et al. Novel surgical technique to selectively remove metastatic axillary lymph nodes in breast cancer patients after neoadjuvant chemotherapy: The MARI procedure—Marking of the axilla with radioactive iodine seeds. Ann Surg. 2014; Apr 16.
  64. 64 - Dowsett M, et al. Meta-analysis of breast cancer outcome in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 20100;28:509-18.
  65. 65 - Drooger JC, Hooning MJ, Seynaeve CM, et al, Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature. Cancer Treat Rev. 2015; Feb;41(2):187-96. doi: 10.1016/j.ctrv.2014.12.002. Epub 2014 Dec 8.
  66. 66 - Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015; Jun 4;372(23):2243-57. doi: 10.1056/NEJMsr1501341. No abstract available.
  67. 67 - EBCTCG, Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet Oncology. 2015; Volume 386, No. 10001, p1341–1352.
  68. 68 - EBCTCG, davies C, Godwin J, Gray R et al. relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet 2011; 378:771-784.
  69. 69 - EBCTCG, Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;
  70. 70 - EBCTCG, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet. 2011; 378: 771-84
  71. 71 - Erbes T, Orlowska-Volk M, ZurHausen A, et al. Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection. BMC Cancer. 2014; 14: 4.
  72. 72 - Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Ca Res Treat 2013; 140: 135-142.
  73. 73 - Fakkert IE, Mourits MJ, et al. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. Cancer Prev Res (Phila) 2012; Nov;5(11):1291-1297.
  74. 74 - Fehrenbacher L, Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014; Jul 10;32(20):2151-8
  75. 75 - Finkelman BS, Rubinstein WS, Friedman S, et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012; Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.
  76. 76 - Fischer B, Dignam J, Bryant J, Wolmark N. Five years versus more than five years of tamoxifen for lymphnode-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 radomized trial. J Natl Cancer Inst. 2001; 93:684-690.
  77. 77 - Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J ClinOncol. 1997; Jul;15(7):2483-93.
  78. 78 - Fitzsullivan E, Lari SA, Smith B, et al. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013; Dec;20(13):4103-12.
  79. 79 - Fontein DB, van de Water W, Mieog JS, et al. Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance. Eur J SurgOncol. 2013; May;39(5):417-24
  80. 80 - Fontein DBY et al. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cance patients- A phase II trial. Eur J Cancer 2014;50:2190-2200.
  81. 81 - Forbes JF, Sestak I, Howell A, et al; IBIS-II investigators Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016; Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.
  82. 82 - Fostira F, Tsitlaidou M, Papadimitriou C, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat. 2012; Jul;134(1):353-62. doi: 10.1007/s10549-012-2021-9. Epub 2012 Mar 21.
  83. 83 - Francis AM, Haugen CE, Grimes LM, et al. Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol. 2015; Dec;22(13):4270-9.
  84. 84 - Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. NEJM 2015; 372: 436-46.
  85. 85 - Freyer G, Campone M, Peron J, et al. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. CritRevOncolHematol. 2011; Dec;80(3):466-73.
  86. 86 - Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J ClinOncol. 2008; Oct 10;26(29):4746-51.
  87. 87 - Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-86.
  88. 88 - Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297-305.
  89. 89 - Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J SurgOncol. 2016; Mar;42(3):361-8.
  90. 90 - Gianni et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016;17:791-800.
  91. 91 - Gianni L et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
  92. 92 - Gianni L, Neoadjuvant and adjuvant trastuzumab in patiënts with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15:640-7.
  93. 93 - Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama. 2011;305(6):569-75.
  94. 94 - Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010; Sep;252(3):426-32.
  95. 95 - Glechner A, Wockel A, Gartlehner G, et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013;49(4):812-25.
  96. 96 - Gnant M et al, Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679-91.
  97. 97 - Gnant M, Mlineritsch B, Stoeger H, et al. Zolendronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrazol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast Cancer and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015; 26: 313-20.
  98. 98 - Gobardhan PD, de Wall LL, van der Laan L, et al. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy. Ann Oncol. 2013;24(3):668-73.
  99. 99 - Goldhirsch A et al, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. 2013; Ann of Oncol 2013;24: 2206
  100. 100 - Goldhirsch A. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013; Sep 21;382(9897):1021-8.
  101. 101 - Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011; Mar 1;17(5):1082-9. doi: 10.1158/1078-0432.CCR-10-2560. Epub 2011 Jan 13.
  102. 102 - Goss PE et al, Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. NEJM. 2016; 375:209-19.
  103. 103 - Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. The New England journal of medicine. 2003; 349: 1793-802.
  104. 104 - Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999; 17(6):1689-700.
  105. 105 - Gray RG, Rea D, Handley K et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 woman with early breast cancer. J Clin Oncol 31. 0000; (suppl 15;5).
  106. 106 - Groen EJ, Elshof LE, Visser LL, et al. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). Breast. 2017; Feb;31:274-83
  107. 107 - Groheux D, Hindié E, Giacchetti S, et al. Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med. 2012; Feb;53(2):249-54.
  108. 108 - Guerrero A, Gavila J, Folkerd E et al. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Ann Oncol 2013; 24: 674-679.
  109. 109 - Hadji P, Coleman RE, Wilson C, et al.Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016;
  110. 110 - Haloua MH, Volders JH, Krekel NM, et al. Intraoperative Ultrasound Guidance in Breast-Conserving Surgery Improves Cosmetic Outcomes and Patient Satisfaction: Results of a Multicenter Randomized Controlled Trial (COBALT). Ann Surg Oncol. 2016; Jan;23(1):30-7.
  111. 111 - Hartman AR, Kaldate RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012; Jun 1;118(11):2787-95. doi: 10.1002/cncr.26576. Epub 2011 Oct 5.
  112. 112 - Hartogh MD den, van den Bongard HJ, Davidson MT, et al. Full-thickness closure in breast-conserving surgery: the impact on radiotherapy target definition for boost and partial breast irradiation. A multimodality image evaluation. Ann Surg Oncol. 2014; Nov;21(12):3774-9. doi: 10.1245/s10434-014-3801-8. Epub 2014 May 30.
  113. 113 - Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al HEBON, Hooning MJ, Seynaeve C. improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015; Feb 1; 136(3): 668-77 (2015B)
  114. 114 - Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al; HEBON, Hooning MJ, Seynaeve C. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015; Feb 1;136(3):668-77. doi: 10.1002/ijc.29032. Epub 2014 Jul 8.
  115. 115 - Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015; Mar 18;107(5):10.1093/jnci/djv033.(2015 A)
  116. 116 - Hennequin C, et al .Irradiation of Internal Mammary Nodes After Mastectomy. Int J Radiat ONcol Biol Phys. 2013;
  117. 117 - Hennessy BT, Hortobagyi GN, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J ClinOncol. 2005;23:9304-11.
  118. 118 - Henry NL, Xia R, Banerjee M et al. Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol 2013; 24: 2011-2016.
  119. 119 - Heuts EM et al, Internal mammary lymph drainage and sentinel node biopsy in breast cancer - A study on 1008 patients. Eur J Surg Oncol. 2009; Mar;35(3):252-7. doi: 10.1016/j.ejso.2008.06.1493. Epub 2008 Aug 5.
  120. 120 - Hieken TJ, et al. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann SurgOncol. 2013; 20: 3199-3204.
  121. 121 - Hindié E, Groheux D, Hennequin C, et al. Lymphoscintigraphy can select breast cancer patients for internal mammary chain radiotherapy. Int J Radiat Oncol Biol Phys. 2012; Jul 15;83(4):1081-8. doi: 10.1016/j.ijrobp.2011.09.016.
  122. 122 - Hogan MP, Goldman DA, Dashevsky B, et al. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. J Nucl Med. 2015; Nov;56(11).
  123. 123 - Houssami N, Macaskill P, Marinovich ML, et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2014; Mar;21(3):717-30.
  124. 124 - ASTRO, https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2016/Updated-ASTRO-guideline-expands-pool-of-suitable-candidates-for-accelerated-partial-breast-irradiation/. 2016;
  125. 125 - Hudis CA, Trastuzumab-mechanism of action and use in clinical practice. NEJM. 2007; 357;39-51.
  126. 126 - Hughes JH, Mason MC, Gray RJ, et al. A multi-site validation trial of radioactive seed localization as an alternative to wire localization. Breast J. 2008;14(2):153-7.
  127. 127 - Hughes KS, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382e7
  128. 128 - Humbert O, Riedinger JM, Charon-Barra C, et al. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2015; Dec 15;21(24):5460-8.
  129. 129 - Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558-66.
  130. 130 - Hwang et al. The Comparative Study of Ultrasonography, Contrast-Enhanced MRI, and (18)F-FDG PET/CT for Detecting Axillary Lymph Node Metastasis in T1 Breast Cancer. J Breast Cancer. 2013; Sep;16(3):315-21.
  131. 131 - Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008; 19: 877-82.
  132. 132 - Jackisch C, Kim SB, Semiglazov V, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol. 2015; Feb;26(2):320-5.
  133. 133 - Jackson L, Bourke AG, Abdul Aziz F, et al. Radioactive seed localisation to guide removal of impalpable lymph nodes (radioguided occult lesion localisation using iodine-125 seeds, "ROLLIS"). BMJ Case Rep. 2014;2014.
  134. 134 - Jagsi R et al, Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol. 2014; Nov 10;32(32):3600-6.
  135. 135 - Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. Journal of the National Cancer Institute. 2007; 99: 1845-53.
  136. 136 - Jin Y. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9.
  137. 137 - Joensuu H, Bono P, Kataja V Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009; Dec 1;27(34):5685-92.
  138. 138 - Joensuu H. , P.L. Kellokumpu-lehtinen, P. Bono, R et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. NEJM. 2006; 354:809-20.
  139. 139 - Joerger M, Thürlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? Ann Oncol. 2011; Jan;22(1):17-23.
  140. 140 - Johnson J, Esserman L, et al. Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome. Ann Surg Oncol. 2016; Mar;23(3):715-21
  141. 141 - Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J ClinOncol. 2009; Mar 10;27(8):1177-83
  142. 142 - Khosla S et al, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; Oct;22(10):1479-91.
  143. 143 - Kirova YM, Savignoni A, Sigal-Zafrani B, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat. 2010; Feb;120(1):119-26. doi: 10.1007/s10549-009-0685-6. Epub 2009 Dec 24.
  144. 144 - Koolen BB et al, Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy. Br J Surg. 2017; Aug;104(9):1188-1196.
  145. 145 - Koolen BB, Pengel KE, Wesseling J, et al. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast. 2013; Oct;22(5):691-7.
  146. 146 - Koolen BB, ValdesOlmos RA, Elkhuizen PHM, et al. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Breast Cancer ResTreat. 2012; 135(1):231–40
  147. 147 - Koolen BB, ValdésOlmos RA, Vogel WV, et al. Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II-III breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013; Sep;141(2):249-54.
  148. 148 - Koolen BB, Vrancken Peeters MJ, Aukema TS, et al. RA.18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat. 2012; Jan;131(1):117-26.
  149. 149 - Koolen BB, Vrancken Peeters MJ, Wesseling J, et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2012; Dec;39(12):1830-8.
  150. 150 - Koolen et al, Early Assessment of Axillary Response with 18F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013; 20:2227–2235; 2)
  151. 151 - Kotsopoulos J, Huzarski T, Gronwald J, et al; Hereditary Breast Cancer Clinical Study Group. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2016; Sep 6;109(1). pii: djw177. doi: 10.1093/jnci/djw177. Print 2017 Jan
  152. 152 - Krag DN, Anderson SJ, Julian TB, et al; National Surgical Adjuvant Breast and Bowel Project.Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007; Oct;8(10):881-8.
  153. 153 - Krammer J, Schnitzer A, Kaiser CG, et al. (18)?F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities? Eur Radiol. 2015; Aug;25(8):2460-9. doi: 10.1007/s00330-015-3630-6. Epub 2015 Feb 15.
  154. 154 - Krekel NM, Haloua MH, Lopes Cardozo AM, et al. Intraoperative ultrasound guidance for palpable breast cancer excision (COBALT trial): a multicentre, randomised controlled trial. Lancet Oncol. 2013; Jan;14(1):48-54. doi: 10.1016/S1470-2045(12)70527-2. Epub 2012 Dec 4.
  155. 155 - Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013; Jun;14(7):609-18. doi: 10.1016/S1470-2045(13)70166-9. Epub 2013 May 15
  156. 156 - Kurian AW et al, Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014; Jul 1;32(19):2001-9.
  157. 157 - Landercasper J, Bennie B, Bray MS, Vang CA, Linebarger JH. Does neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer? Gland Surg. 2017; Feb;6(1):14-26.
  158. 158 - Leal F, Liutti VT, Antunes dos Santos VC, et al. Neoadjuvant endocrine therapy for resectable breast cancer: A systematic review and meta-analysis. Breast. 2015; Aug;24(4):406-12.
  159. 159 - Leonardi MC, Maisonneuve P, Mastropasqua MG, et a. Accelerated partial breast irradiation with intraoperative electrons: using GEC-ESTRO recommendations as guidance for patient selection. Radiother Oncol. 2013; Jan;106(1):21-7
  160. 160 - Li J et al, Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers. Ann Oncol. 2016;
  161. 161 - Liebens FP, Carly B, Pastijn A, et al. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007;43:238-57.
  162. 162 - Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012; Apr;13(4):412-9. doi: 10.1016/S1470-2045(12)70042-6. Epub 2012 Feb 27.
  163. 163 - Liu FF, Shi W, Done SJ, et al. Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. J Clin Oncol. 2015; Jun 20;33(18):2035-40. doi: 10.1200/JCO.2014.57.7999. Epub 2015 May 11
  164. 164 - Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 2015;51:451e463.
  165. 165 - Livi L, Paiar F, Simontacchi G, et al. Loco regional failure pattern after lumpectomy and breast irradiation in 4,185 patients with T1 and T2 breast cancer. Implications for nodal irradiation. Acta Oncol. 2006;45(5):564-70.
  166. 166 - Lovrics PJ, Cornacchi SD, Vora R, et al. Systematic review of radioguided surgery for non-palpable breast cancer. Eur J SurgOncol. 2011;37(5):388-97.
  167. 167 - Luiten JD, Beek MA, Voogd AC, et al. Iodine seed- versus wire-guided localization in breast-conserving surgery for non-palpable ductal carcinoma in situ. Br J Surg. 2015;
  168. 168 - Maaren MC van, de Munck L, de Bock GH, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016; Aug;17(8):1158-70. doi: 10.1016/S1470-2045(16)30067-5. Epub 2016 Jun 22.
  169. 169 - Madsen EV, Aalders KC, van der Heiden-van der Loo M, Gobardhan PD, van Oort PM, van der Ent FW, Rutgers EJ, Valdés Olmes RA, Elias SG, van Dalen T Prognostic Significance of Tumor-Positive Internal Mammary Sentinel Lymph Nodes in Breast Cancer: A Multicenter Cohort Study. Ann Surg Oncol. 2015; Dec;22(13):4254-62. doi: 10.1245/s10434-015-4535-y. Epub 2015 Mar 26.
  170. 170 - Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J ClinOncol. 2012;30:3960-6.
  171. 171 - Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008; 26: 1965-71.
  172. 172 - Mamounas EP, Tang G, Liu Q. The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NASPB experience. JCO 2014; 110: 45-50
  173. 173 - Mamtani A, Barrio AV, King TA, et al. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a ProspectiveStudy. Ann SurgOncol. 2016; 23:3467–3474.
  174. 174 - Marinovich ML, Houssami N, Macaskill P, et al. Accuracy of ultrasound for predicting pathologic response during neoadjuvant therapy for breast cancer. Int J Cancer. 2015; Jun 1;136(11):2730-7.
  175. 175 - Martin M, Pienkowski T, Mackey J, et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; Jun 2;352(22):2302-13.
  176. 176 - Mavaddat N, Peock S, Frost D, et al; EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013; Jun 5;105(11):812-22. doi: 10.1093/jnci/djt095. Epub 2013 Apr 29.
  177. 177 - Mavroudis D, Saloustros E, Malamos N. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015; Jul;26(7):1333-40.
  178. 178 - McGhan LJ, Dueck AC, Gray RJ, et al. The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol. 2012; Sep 1;106(3):254-9
  179. 179 - Meijnen P, Oldenburg HS, Loo CE, et al. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg. 2007; Aug;94(8):952-6.
  180. 180 - Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer. 2011; Apr 12;doi:10.1038/bjc.2011.120.
  181. 181 - Metzger-Filho O et al, Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013; 31: 3083-3090.
  182. 182 - Meyer P, Landgraf K, Högel B, et al. BRCA2 mutations and triple-negative breast cancer. PLoS One. 2012;7(5):e38361. doi: 10.1371/journal.pone.0038361. Epub 2012 May 30.
  183. 183 - Monteau A, Sigal-Zafrani B, Kirova YM, et al. Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage. Int J Radiat Oncol Biol Phys. 2009; Nov 15;75(4):1021-8.
  184. 184 - Moran MS, Zhao Y, Ma S, Kirova Y Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy. JAMA Oncol. 2017; Aug 1;3(8):1060-1068.
  185. 185 - Mougalian SS et al, Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016; Apr;2(4):508-16.
  186. 186 - Muendlein A, Rohde BH, Gasser K, et al. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J Cancer Res Clin Oncol. 2015; Nov;141(11):2005-12. doi: 10.1007/s00432-015-1986-2. Epub 2015 May 15.
  187. 187 - Mukesh MB, Barnett G, Cumming J, et al. Association of breast tumour bed seroma with post-operative complications and late normal tissue toxicity: results from the Cambridge Breast IMRT trial. Eur J Surg Oncol. 2012; Oct;38(10):918-24. doi: 10.1016/j.ejso.2012.05.008. Epub 2012 Jun 14.
  188. 188 - Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.J Clin Oncol. 2016; Apr 10;34(11):1208-16. doi: 10.1200/JCO.2015.63.3594. Epub 2016 Feb 16.
  189. 189 - National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII Phase 2. Washington, DC: The National Academies Press, 2006;
  190. 190 - NCCN, guideline breast cancer. 0000;
  191. 191 - Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26: 2373-8.
  192. 192 - Norum J, Andreassen T. Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective? Anticancer Res 2000; 20: 2193-6
  193. 193 - Nottegar A, Veronese N, Senthil M, et al. Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis. Eur J Surg Oncol. 2016; Jul;42(7):919-25. doi: 10.1016/j.ejso.2016.02.259. Epub 2016 Mar 10.
  194. 194 - Obdeijn IM, Heijnsdijk EAM, et al. Mammographic screening in BRCA1 mutation carriers postponed until age 40: evaluation of benefits, costs and radiation risks using models. Eur J C 2016;63:135-142.
  195. 195 - Obdeijn IM, Winter-Warnars GAO, Mann RM, et al. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study. Breast Cancer Res Treat 2014;144(3):577-82. DOI 10.1007/s10549-014-2888-8
  196. 196 - Olivotto I, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from RAPID: A randomized trial of accelerated partial breast irradiation using 3D conformal external beam radiation therapy. J Clin Oncol 2013;31:4038e4045.
  197. 197 - O'Sullivan CC, Bradbury I, Campbell C. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors = 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol. 2015; Aug 20;33(24):2600-8.
  198. 198 - Ouldamer L, Bonastre J, Brunet-Houdard S, et al. Dead space closure with quilting suture versus conventional closure with drainage for the prevention of seroma after mastectomy for breast cancer (QUISERMAS): protocol for a multicentre randomised controlled trial. BMJ Open. 2016; Apr 4;6(4):e009903. doi: 10.1136/bmjopen-2015-009903
  199. 199 - Ouldamer L, Caille A, Giraudeau B, et al. Quilting Suture of Mastectomy Dead Space Compared with Conventional Closure with Drain. Ann Surg Oncol. 2015; Dec;22(13):4233-40. doi: 10.1245/s10434-015-4511-6. Epub 2015 Mar 18.
  200. 200 - Ozen M, Gunduz M, Ates O Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients. J BUON. 2016; Jul-Aug;21(4):799-808.
  201. 201 - Pagani O, Reg Tan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. NEJM 2014; 371: 107-18.
  202. 202 - Palomba G, Budroni M, Olmeo N, et al. Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. Oncol Lett. 2014; Apr;7(4):948-952. Epub 2014; Jan 28.
  203. 203 - Pan H, Wu N, Ding H, et al. Intraoperative ultrasound guidance is associated with clear lumpectomy margins for breast cancer: a systematic review and meta-analysis. PLoS One. 2013; Sep 20;8(9):e74028. doi: 10.1371/journal.pone.0074028. eCollection 2013
  204. 204 - Pengel KE, Koolen BB, Loo CE, et al. Combined use of ¹8F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014; Aug;41(8):1515-24.
  205. 205 - Pepels MJ, Vestjens JH, de Boer M, et al. Models predicting non-sentinel node involvement also predict for regional recurrence in breast cancer patients without axillary treatment. Eur J Surg Oncol. 2013; Dec;39(12):1351-7. doi: 10.1016/j.ejso.2013.09.006.
  206. 206 - Perez EA, Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; Nov 20;32(33):3744-52
  207. 207 - Pern F, Bogdanova N, Schürmann P, et al. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One. 2012;7(10):e47993. doi: 10.1371/journal.pone.0047993. Epub 2012 Oct 24.
  208. 208 - Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Lonati V, Barni S. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. Breast Cancer Res Treatm. 2013; 140: 233-40. 10.1007/s10549-013-2629-4.
  209. 209 - Phi X-A, Houssami N, Obdeijn IM, et al. Magnetic Resonance imaging improves breast screening sensitivity in BRCA mutation carriers age = 50 Years: evidence from an individual patient data meta-analysis. J Clin Oncol 2015;33(4):349-356.
  210. 210 - Phi X-A, Saadatmand S, de Bock GH, et al. Contribution of mammografie to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. British Journal of Cancer 2016;114(6):631-7.
  211. 211 - Piccart MJ, Gingras I. Breast cancer in 2015: Academic research sheds light on issues that matter to patients. Nat Rev Clin Oncol. 2016; Feb;13(2):67-8
  212. 212 - Piccart-Gebhart MJ, Procter M, Leyland-Jones B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; Oct 20;353(16):1659-72.
  213. 213 - Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.Breast Cancer Res Treat. 2010; Jun;121(2):389-98. doi: 10.1007/s10549-010-0894-z. Epub 2010 Apr 22.
  214. 214 - Pijpe A, Andrieu N, Easton DF, et al; GENEPSO; EMBRACE; HEBON. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 2012; Sep 6;345:e5660. doi: 10.1136/bmj.e5660.
  215. 215 - Pilewskie M, Olcese C, Eaton A, et al. Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation. Ann Surg Oncol. 2014; May;21(5):1552-60.
  216. 216 - Pivot X et al, 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013; Jul;14(8):741-8.
  217. 217 - Pivot X: Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014; Oct;25(10):1979-87
  218. 218 - Plecha D, Bai S, Patterson H, et al. Improving the Accuracy of Axillary Lymph Node Surgery in Breast Cancer with Ultrasound-Guided Wire Localization of Biopsy Proven Metastatic Lymph Nodes. Ann SurgOncol. 2015;
  219. 219 - Polgar C, Major T, Fodor J, et al. Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother Oncol 2010;94:274e279.
  220. 220 - Poortmans P, Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet. 2014; Jun 21;383(9935):2104-6.
  221. 221 - Poortmans PM, Arenas M, Livi L. Over-irradiation. Breast. 2017; Feb;31:295-302
  222. 222 - Poortmans PM, Collette S, Kirkove C, et al. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med 2015;373(4):317-27.
  223. 223 - Postma EL, Verkooijen HM, van Esser S, et al. Efficacy of 'radioguided occult lesion localisation' (ROLL) versus 'wire-guided localisation' (WGL) in breast conserving surgery for non-palpable breast cancer: a randomised controlled multicentre trial. Breast Cancer ResTreat. 2012;136(2):469-78.
  224. 224 - Pouw B, de Wit-van der Veen LJ, Stokkel MP, et al. Heading toward radioactive seed localization in non-palpable breast cancer surgery? A meta-analysis. J SurgOncol. 2015; Feb;111(2):185-91.
  225. 225 - Powell SN, Kachnic. LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003;22:5784-5791
  226. 226 - Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8(2):R13.
  227. 227 - Prendeville S, Ryan C, Feeley L, et al. Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. Breast. 2015; Jun;24(3):197-200.
  228. 228 - Preston DL, Mattson A, Holmberg E, et al. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiation Research. 2002;158(2):220-235
  229. 229 - Prevos R, Smidt ML, Tjan-Heijnen VC, et al. Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review. EurRadiol. 2012; Dec;22(12):2607-16.
  230. 230 - Price J, Chen SW. Mammographically screen-detected asymmetric densities with architectural distortion and normal ultrasound at assessment: Value of MRI as a problem-solving tool. J Med Imaging RadiatOncol. 2015; Jun;59(3):312-9.
  231. 231 - Provencher L, Hogue JC, Desbiens C, et al. Is clinical breast examination important for breast cancer detection? Curr Oncol. 2016; Aug;23(4):e332-9. doi: 10.3747/co.23.2881. Epub 2016 Aug 12.
  232. 232 - Qvamme G, Axelsson CK, Lanng C, et al. Randomized clinical trial of prevention of seroma formation after mastectomy by local methylprednisolone injection. Br J Surg. 2015;102(10):1195-203.
  233. 233 - Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015; Jul;152(2):389-98.
  234. 234 - Ram R, Singh J, McCaig E. Sentinel Node Biopsy Alone versus Completion Axillary Node Dissection in Node Positive Breast Cancer: Systematic Review and Meta-Analysis. International Journal of Breast Cancer. 2014;513780.
  235. 235 - Rao R et al, Axillary node interventions in breast cancer: a systematic review. Jama. 2013;310(13):1385-94.
  236. 236 - Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009; Jan 21;101(2):80-87.
  237. 237 - Recht A, Comen EA, Fine RE, et al. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J ClinOncol. 2016; Dec 20;34(36):4431-4442.
  238. 238 - Renaudeau C, Lefebvre-Lacoeuille C, Campion L, et al. Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study. Breast. 2016; Aug;28:54-9.
  239. 239 - Riegger et al, Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients. Acta Radiol. 2012; Dec 1;53(10):1092-8.
  240. 240 - Robertson L, Hanson H, Seal S, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012; Mar 13;106(6):1234-8. doi: 10.1038/bjc.2012.31. Epub 2012 Feb 14.
  241. 241 - Rodriguez N, Sanz X, Dengra J, et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2013;87:1051e1057.
  242. 242 - Roeke T, van Bommel AC, Gaillard-Hemmink MP, et al. The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review. Breast Cancer Res Treat. 2014; Aug;147(1):15-23. doi: 10.1007/s10549-014-3074-8. Epub 2014 Aug 8.
  243. 243 - Romond E, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer: combined analysis of NSABP-B31/NCCTG-N9831. N Engl J Med. 2005; 353:1673-84.
  244. 244 - Rouanet P, Roger P, Rousseau E. HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. Cancer Med. 2014; Feb;3(1):134-42. doi:
  245. 245 - Rummel S, Varner E, Shriver CD, et al. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat. 2013; Jan;137(1):119-25. doi: 10.1007/s10549-012-2348-2. Epub 2012 Nov 29.
  246. 246 - Rusch P, Hoffmann O, Stickelmann AL, et al. Distant metastasis detected by routine staging in breast cancer patients participating in the national German screening programme: consequences for clinical practice. Springerplus. 2016; Jul 7;5(1):1010. doi: 10.1186/s40064-016-2703-6. eCollection 2016.
  247. 247 - Rusthoven CG, Rabinovitch RA, Jones BL, et al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol. 2016; May; 27(5): 818-27.
  248. 248 - Ryden L, et al. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast 2016;26:106-14.
  249. 249 - Saadatmand S, Vos JR, Hooning MJ, et al. Relevance and efficacy of breast canecr screening in BRCA1 and BRCA2 mutation carriers above 60 years; a national cohort study. International Journal of Cancer 2014;135(12)2940-9.
  250. 250 - Saarto T, Vehmanen L, Virkkunen P, et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004;43(7):650-6.
  251. 251 - Samant R, Ganguly P. Staging investigations in patients with breast cancer: the role of bone scans and liver imaging. Arch Surg 1999; 134: 551-3.
  252. 252 - Sanders ME et al, The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005; Jun 15;103(12):2481-4
  253. 253 - Schipper RJ, Moossdorff M, Beets-Tan RGH, Smidt ML, Lobbes MBI. Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review. Eur J Radiol. 2015; Jan;84(1):41-47.
  254. 254 - Schmidt MK, Hogervorst F, van Hien R, et al. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol. 2016; Aug 10;34(23):2750-60. doi: 10.1200/JCO.2016.66.5844. Epub 2016 Jun 6.
  255. 255 - Schmitz A et al, Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. PloS one. 2017; May 22; 12(5), e0176782.
  256. 256 - Schneider BP, Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer. 2015; Dec 22;113(12):1651-7.
  257. 257 - Schwentner L, Helms G, Nekljudova V, et al. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial. Breast. 2017; Feb;31:202-207.
  258. 258 - Senkus E et al, Primary Breast Cancer: ESMO Clinical Practice Guidelines ESMO guidelines. Ann Oncol. 2015; 26 (suppl 5): v8-v30.
  259. 259 - Sestak I, Dowsett M et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 2013; 105: 1504-11.
  260. 260 - Shachar SS, Hurria A, Muss HB. Breast Cancer in Women Older Than 80 Years. J Oncol Pract. 2016; Feb;12(2):123-32
  261. 261 - Shaikh T, Narra V, Goyal S, et al. Lumpectomy closure technique does not affect dosimetry in patients undergoing external-beam-based accelerated partial breast irradiation. Ann Surg Oncol. 2013; Apr;20(4):1323-8. doi: 10.1245/s10434-012-2775-7. Epub 2012 Dec 11.
  262. 262 - Sharek D, Zuley ML, Zhang JY, et al. Radioactive seed localization versus wire localization for lumpectomies: a comparison of outcomes. AJR Am J Roentgenol. 2015;204(4):872-7.
  263. 263 - Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014; June; 145(3): 707–714. doi:10.1007/s10549-014-2980-0.
  264. 264 - Simos D, Catley C, van Walraven C, et al. Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. CMAJ. 2015; Sep 8;187(12):E387-97. doi: 10.1503/cmaj.150003. Epub 2015 Jun 22.
  265. 265 - Slamon D, Eiermann W, Robert N, et al, Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; Oct 6;365(14):1273-83.
  266. 266 - Smith IE, Dowsett M, Yap YS et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006; 24: 2444-2447.
  267. 267 - Smith L, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36.
  268. 268 - Solá M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Annals of surgical oncology. 2013;20(1):120-7.
  269. 269 - Solin LJ et al, A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013; May 15;105(10):701-10. doi: 10.1093/jnci/djt067. Epub 2013 May 2.
  270. 270 - Soucy G, Bélanger J, Leblanc G, et al. Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact? J Am Coll Surg. 2008; Jun;206(6):1116-21.
  271. 271 - Spielmann M, Roché H, Delozier T Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009; Dec 20;27(36):6129-34.
  272. 272 - Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast. 2014; Oct;23(5):546-51
  273. 273 - Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review. 2012; Oct;17(10)
  274. 274 - Stearns V ea, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003; 95:1758-64.
  275. 275 - Stewart HJ et al, Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001; 93: 456-62.
  276. 276 - Stewart HJ, Prescott RJ, Forrest AP. Scottisch adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93:456-462
  277. 277 - Straver ME, Loo CE, Alderliesten T, et al. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. Br J Surg. 2010; Aug;97(8):1226-31.
  278. 278 - Straver ME, Rutgers EJ, Oldenburg HS, et al. Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy. Am J Surg. 2009; Jul;198(1):46-50.
  279. 279 - Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breastconserving surgery for low-risk invasive and in-situ carcinoma of the female breast: A randomised, phase 3, non-inferiority trial. Lancet 2016;387:229e238.
  280. 280 - Suter T, Procter M, van Veldhuisen D, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25;3859-65
  281. 281 - Tang G, Liu Q. The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience. J Surg Oncol. 2014; Jul;110(1):45-50. doi: 10.1002/jso.23609.
  282. 282 - Taylor DB, Bourke AG, Westcott E, et al. Radioguided occult lesion localisation using iodine-125 seeds ('ROLLIS') for removal of impalpable breast lesions: First Australian experience. J Med Imaging RadiatOncol. 2015;59(4):411-20.
  283. 283 - Teixeira et al, Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer. Clin Nucl Med. 2016;41: 181–6.
  284. 284 - Teixeira et al, PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease. Eur J Surg Oncol. 2017; Apr;43(4):625-635.
  285. 285 - Teixeira SC, Koolen BB, Elkhuizen PH, et al. PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease. Eur J SurgOncol. 2016; Oct 31. pii: S0748-7983(16)30950-7.
  286. 286 - Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25:3525-33.
  287. 287 - Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014; 32: 3948-58.
  288. 288 - Thompson ER et al, Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls. Breast Cancer Res. 2015; Aug 19;17(1):111.
  289. 289 - Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. J Clin Oncol. 2016; Feb 1;34(4):314-20. doi: 10.1200/JCO.2015.63.6456. Epub 2015 Nov 23.
  290. 290 - Tjan-Heijnen V et al, DATA study. In press. 2017;
  291. 291 - Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015; Jan 8;372(2):134-41.
  292. 292 - Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst. 1996; 88: 1828-33.
  293. 293 - Tung N, Domcheck SM, Stadler Z et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016; Sep;13(9):581-8.
  294. 294 - Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23: 1111-30
  295. 295 - Goss et al, J Natl Cancer Institute. 2005; 97:1262-71 en Jin ea JCO 2012; 30: 718
  296. 296 - Valachis A, Nearchou AD, Lind P Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014; Apr;144(3):443-55. doi: 10.1007/s10549-014-2890-1. Epub 2014 Feb 25.
  297. 297 - Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014; Apr;144(3):443-55. doi: 10.1007/s10549-014-2890-1. Epub 2014 Feb 25
  298. 298 - Valejo FA et al, Volume of breast tissue excised during breast-conserving surgery in patients undergoing preoperative systemic therapy. Rev Bras GinecolObstet. 2013; May;35(5):221-5.
  299. 299 - van den Einden LC, Aben KK, Massuger LF, et al. Successful centralisation of patients with vulvar carcinoma: a population-based study in The Netherlands. Eur J Cancer. 2012; Sep;48(13):1997-2003. doi: 10.1016/j.ejca.2012.01.030. Epub 2012 Mar 1.
  300. 300 - van den Hoven I, Kuijt G, Roumen R, et al. A head to head comparison of nine tools predicting non-sentinel lymph node status in sentinel node positive breast cancer women. J Surg Oncol. 2015; Aug;112(2):133-8.
  301. 301 - van den Hoven I, van Klaveren D, Voogd AC, et al. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients. Clin Breast Cancer. 2015; Sep 21. pii: S1526-8209(15)00214-1. doi: 10.1016/j.clbc.2015.09.003.
  302. 302 - van der Noordaa ME, Pengel KE, Groen E, et al. The use of radioactive iodine-125 seed localization in patients with non-palpable breast cancer: a comparison with the radioguided occult lesion localization with 99m technetium. Eur J SurgOncol. 2015;41(4):553-8.
  303. 303 - Van Hellemond IEG et al, Ovarian function recovery during anastrazole in breast cancer patients with chemotherapy-induced ovarian function failure. In press JNCI. 2017;
  304. 304 - van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000; Feb;18(3):487-97.)
  305. 305 - van Nijnatten TJ et al, A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study. Clin Breast Cancer. 2017; Aug;17(5):399-402.
  306. 306 - van Nijnatten TJ, Schipper RJ, Lobbes MB, Nelemans PJ, Beets-Tan RG, Smidt ML. The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis Eur J Surg Oncol. 2015; Oct;41(10):1278-87.
  307. 307 - van Os NJ, Roeleveld N Weemaes CM, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. 2016; Aug;90(2):105-17. doi: 10.1111/cge.12710. Epub 2016 Jan 20.
  308. 308 - van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, et al. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat. 2016; Jul;158(2):361-71.
  309. 309 - van Riet YE, Maaskant AJ, Creemers GJ, et al. Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed. Eur J SurgOncol. 2010;36(2):164-9.
  310. 310 - van Roozendaal LM, Goorts B, Klinkert M, et al. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Res Treat. 2016; Apr;156(3):517-25.
  311. 311 - Vaz-Luis I, Keating NL, Lin NU, et al. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014; Mar 20;32(9):927-34.
  312. 312 - Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013; Dec;14(13):1269-77. doi: 10.1016/S1470-2045(13)70497-2. Epub 2013 Nov 11.
  313. 313 - Vliek SB et al, Adjuvant ibandronat in postmenopausal women with early breast cancer. SABCS. 2016; Abstract S6-02
  314. 314 - Volders JH, Haloua MH, Krekel NM, et al.; “the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA)” Neoadjuvant chemotherapy in breast-conserving surgery - Consequences on margin status and excision volumes: A nationwide pathology study.Eur J SurgOncol. 2016; Jul;42(7):986-93.
  315. 315 - von Minckwitz G et al, Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; Jun;15(7):747-56.
  316. 316 - von Minckwitz G, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J ClinOncol. 2012; 30:1796-804.
  317. 317 - Voogd AC, Rutgers EJTh, Leeuwen FE van. Welke factoren beïnvloeden de kans op borstkanker? In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven RIVM. 2014; Nationaalkompas.nl
  318. 318 - Vos JR, Hsu L, Brohet RM, et al. Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers. J Clin Oncol. 2015; Aug 10;33(23):2553-62. doi: 10.1200/JCO.2014.59.0463. Epub 2015 Jul 6.
  319. 319 - Vrieling C, van Werkhoven E, Maingon P et al, European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups. Prognostic Factors For Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial. JAMA Oncol. 2016; Sep 8. doi: 10.1001/jamaoncol.2016.3031. [Epub ahead of print]
  320. 320 - Vriens BE, Aarts MJ, de Vries B, et al; Breast Cancer Trialists' Group of the Netherlands (BOOG).Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. Eur J Cancer. 2013; Oct;49(15):3102-10.
  321. 321 - Vriens BE, de Vries B, Lobbes MB, et al; INTENS Study Group. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer. Eur J Cancer. 2016; Jan;52:67-76.
  322. 322 - Waaijer L, Willems SM, Verkooijen HM, et al. Impact of preoperative evaluation of tumour grade by core needle biopsy on clinical risk assessment and patient selection for adjuvant systemic treatment in breast cancer. Br J Surg. 2015; Aug;102(9):1048-55.
  323. 323 - Wang Z, Wu L-C, Chen J-Q. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129(3):675-89.
  324. 324 - Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010; Apr;95(4):1555-65.
  325. 325 - Weischer M et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008; Feb 1;26(4):542-8.
  326. 326 - Whelan TJ et al, Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015; 373(4):307-16.
  327. 327 - Wolde B ten, van den Wildenberg FJ, Keemers-Gels ME, et al. Quilting prevents seroma formation following breast cancer surgery: closing the dead space by quilting prevents seroma following axillary lymph node dissection and mastectomy. Ann Surg Oncol. 2014; Mar;21(3):802-7. doi: 10.1245/s10434-013-3359-x. Epub 2013 Nov 12
  328. 328 - Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J ClinOncol. 2013; Nov 1;31(31):3997-4013.
  329. 329 - Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015; Feb;150(1):71-80. doi: 10.1007/s10549-015-3293-7. Epub. 2015; Feb 15.
  330. 330 - Woo S-B et al, Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Int Med. 2006; 144:753-61.
  331. 331 - Yan S, Li K, Jiao X, Zou H. Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials. Onco Targets Ther 2015; 8: 1433-41
  332. 332 - Yang Y et al. CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls. Asian Pac J Cancer Prev. 2012;13(7):3501-5.
  333. 333 - Yates L, Kirby A, Crichton S, et al. Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes. Int J Radiat Oncol Biol Phys. 2012; Apr 1;82(5):2093-103.
  334. 334 - Yi M, Meric-Bernstam F, Kuerer HM, et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012; Feb 20;30(6):600-7. doi: 10.1200/JCO.2011.36.4976. Epub 2012 Jan 17.

Overwegingen

De indicatie en keuze van chemotherapie hangt af van tumorkarakteristieken, leeftijd en performance, conform adjuvante chemotherapie.

Autorisatiedatum en geldigheid

Laatst beoordeeld : 01-07-2018

Laatst geautoriseerd : 31-12-2017

Initiatief en autorisatie

Initiatief : Nederlandse Internisten Vereniging

Geautoriseerd door:
  • Nederlandse Internisten Vereniging
  • Nederlandse Vereniging voor Heelkunde
  • Nederlandse Vereniging voor Nucleaire geneeskunde
  • Nederlandse Vereniging voor Pathologie
  • Nederlandse Vereniging voor Radiologie
  • Nederlandse Vereniging voor Radiotherapie en Oncologie
  • Vereniging Klinische Genetica Nederland

Algemene gegevens

De werkgroep werd procedureel en secretarieel ondersteund door Integraal Kankercentrum Nederland (IKNL). Financiering is (deels) verkregen via IKNL en deel via de Federatie van Medisch Specialisten in het kader van de Stichting Kwaliteitsgelden Medisch Specialisten (SKMS). Deze subsidie had niet tot stand kunnen komen zonder de uitgebreide hulp van de Nederlandse Internisten Vereniging (NIV).

Doel en doelgroep

Deze richtlijn is een document met aanbevelingen en handelingsinstructies ter ondersteuning van de dagelijkse praktijkvoering. De richtlijn berust op de resultaten van wetenschappelijk onderzoek en aansluitende meningsvorming gericht op het vaststellen van goed medisch handelen. Er wordt aangegeven wat in het algemeen de beste zorg is voor de vrouw met (verdenking op) borstkanker of voor hen die voor screening in aanmerking komen. De richtlijn beoogt een leidraad te geven voor de dagelijkse praktijk van de screening, diagnostiek, behandeling en nazorg van borstkanker. Tevens wordt deze richtlijn gebruikt voor het maken van informatiemateriaal voor patiënten, in samenwerking met kanker.nl

 

Gebruikers richtlijn 
Deze richtlijn is geschreven voor alle leden van de beroepsgroepen die aan de ontwikkeling van deze richtlijn hebben bijgedragen. Deze staan vermeld in de colofon (zie {bijlage 1}). 

Samenstelling werkgroep

Voor de revisie van de richtlijn is een kerngroep bestaande uit een radioloog, chirurg, patholoog, medisch-oncoloog, radiotherapeut, verpleegundig specialist en vertegenwoordiger uit de BVN en het NABON gestart met de voorbereidingen op de revisie. Voor de uitvoering van de revisie is begin 2015 een multidisciplinaire werkgroep ingesteld, bestaande uit gemandateerde vertegenwoordigers van alle relevante specialismen die met borstkanker te maken hebben, samen met twee afgevaardigden van de BorstkankerVereniging Nederland (BVN). De voordelen van een dergelijke multidisciplinaire benadering zijn duidelijk: niet alleen wordt hiermee de zorg het best weerspiegeld, ook zal het draagvlak voor de richtlijn optimaal zijn. Bij het samenstellen van de werkgroep is zoveel mogelijk rekening gehouden met de geografische spreiding van de werkgroepleden, evenredige vertegenwoordiging van de diverse betrokken verenigingen en instanties, evenals een spreiding in academische achtergrond.

 

Voorzitter
dr. C.H. Smorenburg, internist-oncoloog, NKI-AVL Amsterdam, namens NIV/NVMO

 

Kerngroep
prof. dr. L.J. Boersma, radiotherapeut-oncoloog, MAASTRO clinic Maastricht, namens NVRO
drs. D. Hairwassers, belangenbehartiger/ervaringsdeskundige, namens BVN

dr. A.I.M. Obdeijn, radioloog, Erasmus MC Rotterdam, namens NVVR

dr. M.J.C. van der Sangen, radiotherapeut-oncoloog, Catharina Ziekenhuis Eindhoven, namens NABON
G.M. Smit MANP, verpleegkundig specialist mammacare, Waterlandziekenhuis Purmerend, namens V&VN
dr. L.J.A. Strobbe, chirurg-oncoloog, Canisius-Wilhelmina Ziekenhuis Nijmegen, namens NVVH/NVCO
dr. J. Wesseling, patholoog, NKI-AVL Amsterdam, namens NVVP

Werkgroep
prof. dr. F. Amant, gynaecoloog, NKI-AVL Amsterdam, op persoonlijke titel

dr. C.D.L. Bavelaar, nucleair geneeskundige, Ziekenhuis Gelderse Vallei, namens NVNG
prof. dr. G.H. de Bock, epidemioloog, UMC Groningen, namens NHG
dr. H.J.G.D. van den Bongard, radiotherapeut-oncoloog, UMC Utrecht, namens NVRO

M.M.A.Brood-van Zanten, arts endocrinologische gynaecologie, VUmc, AMC, NKI-AVL Amsterdam, namens NVOG

dr. N. Bijker, radiotherapeut-oncoloog, Academisch Medisch Centrum Amsterdam, namens NVRO

prof. dr. P.J. van Diest, patholoog, UMC Utrecht, namens NVVP
dr. F. van Duijnhoven, chirurg-oncoloog, NKI-AVL, namens NVVH/NVCO

P. Gielink MSc, oedeemtherapeut, namens NVFL
dr. H. de Graaf, internist-oncoloog, Medisch Centrum Leeuwarden, namens NIV/NVMO
drs. M.W. Imhof, radioloog, Radboud UMC Nijmegen, namens NVVR
dr. A. Jager, internist-oncoloog, Erasmus MC Rotterdam, namens NIV/NVMO

dr. L. Jansen, chirurg-oncoloog, UMC Groningen, namens NVVH/NVCO
dr. C.M. Kets, klinisch geneticus, Radboud UMC Nijmegen, namens VKGN
dr. J.R. Kroep, internist-oncoloog, LUMC, namens NIV/NVMO
dr. M.B.I. Lobbes, radioloog, MUMC Maastricht, namens NVVR
dr. J.H. Maduro, radiotherapeut-oncoloog, UMC Groningen, namens NVRO

dr. C. Meeuwis, radioloog, Rijnstate Ziekenhuis Arnhem, namens NVVR

dr. J.W.S. Merkus, chirurg-oncoloog, HagaZiekenhuis den Haag, namens NVVH/NVCO
M. van Oirsouw, belangenbehartiger/ervaringsdeskundige, namens BVN
dr. J.C. Oosterwijk, klinisch geneticus, UMC Groningen, namens VKGN
dr. L.M. Pereira, nucleair geneeskundige, Alrijne Ziekenhuis Leiderdorp, namens NVNG
dr. A.N. Scholten, radiotherapeut-oncoloog, NKI-AVL Amsterdam, namens NVRO

dr. M.J. Schroevers, psycholoog, UMC Groningen, namens NVPO
Prof. dr. S.A. Scherjon, gynaecoloog-oncoloog, UMC Groningen, namens NVOG
dr. C.M.J.C. Seynaeve, internist-oncoloog, Erasmus MC Rotterdam, namens NVMO
dr. M.L. Smidt, chirurg-oncoloog, MUMC Maastricht, namens NVVH/NVCO
dr. G. van Tienhoven, radiotherapeut-oncoloog, AMC, namens NVRO
drs. B.E.P.J. Vriens, internist-oncoloog, Catharina Ziekenhuis Eindhoven, namens NIV/NVMO
dr. P.J. Westenend, patholoog, Pathologisch laboratorium voor Dordrecht e.o., namens NVVP
drs. H.W. Wiersma, radioloog, Ziekenhuis Gelders Vallei Ede, namens NVVR

drs. L.M.H. Wijers, radioloog, Alrijne Ziekenhuis Leiderdorp, namens NVVR

dr. A.J. Witkamp, chirurg-oncoloog, UMC Utrecht, namens NVVH/NVCO
dr. L.A.E. Woerdeman, plastisch chirurg, NKI-AVL Amsterdam, namens NVPC

 

Procesbegeleiding

drs. T. (Thijs) van Vegchel adviseur richtlijnontwikkeling IKNL

t.vanvegchel@iknl.nl

t 06 549 33 424

 

Ondersteuning

S. Janssen, secretaresse IKNL

Belangenverklaringen

 

persoonlijke financiële belangen

Zijn er mensen uit uw directe persoonlijke omgeving met financiële belangen?              

wetenschappelijk onderzoek gefinancierd door een partij die mogelijk baat heeft bij de uitkomst van een aanbeveling

persoonlijke intellectuele belangen

'Bavelaar, Carine'

nee

nee

nee

nee

'N. Bijker

nee

nee

nee

nee

'g.h.de.bock

nee

nee

nee

nee

'liesbeth.boersma'

nee

nee

nee

nee

'D.vandenBongard

 

 

 

 

'p.j.vandiest

 

 

 

 

'f.v.duijnhoven

nee

nee

nee

nee

pdcgielink

 

 

 

 

'Graaf de, Hiltje'

nee

nee

nee

nee

'f.groenman

nee

nee

nee

nee

desireehairwassers

nee

nee

nee

nee

'Mechli.Imhof-Tas

nee

nee

nee

nee

a.jager

nee

nee

nee

nee

'l.jansen

 

 

 

 

'marleen.kets

nee

nee

nee

nee

'J.R.Kroep

 

 

 

 

Lobbes M.B.I

nee

nee

ja, 1x project gefinancieerd door zonmw en ge healthcare obv contrast mammografie. door de betrokkenheid van zonmw is gegarandeerd dat gehc geen voorkeurspositie kent voor deze studie. tevens zijn er andere aanbieders van cesm op de markt

nee

'j.h. maduro

 

 

 

 

C Meeuwis

 

 

 

 

'm.a.de meij

nee

nee

nee

nee

'j. merkus

nee

nee

nee

nee

'j.c. oosterwijk

nee

nee

nee

nee

MA v oirsouw

nee

nee

nee

nee

'a. obdeijn

nee

nee

nee

nee

'Pereira Arias - Bouda, Lenka'

nee

nee

nee

nee

'maurice.vd.sangen

nee

nee

nee

nee

c.p.schroder

 

 

 

 

M.L. Smidt

nee

nee

nee

nee

'a.scholten

nee

nee

nee

nee

A.P. Schouten

nee

nee

nee

nee

'm.j.schroevers

nee

nee

nee

nee

'c.seynaeve

 

 

 

 

T Smit

nee

nee

nee

nee

'c.smorenburg

nee

nee

nee

nee

'ljastrobbe

nee

nee

nee

nee

'Birgit Vriens

 

 

 

 

pwestenend

nee

nee

nee

nee

'j.wesseling

nee

nee

nee

nee

'Wiersma, Hiske'

nee

nee

nee

nee

'a.j.witkamp

nee

nee

nee

nee

'Jolanda Wittenberg

nee

nee

nee

nee

L. Woerdeman

nee

nee

nee

nee

'Wijers, LMH';

nee

nee

nee

nee

Inbreng patiëntenperspectief

Voor de uitvoering van de revisie is begin 2015 een multidisciplinaire werkgroep ingesteld, bestaande uit gemandateerde vertegenwoordigers van alle relevante specialismen die met borstkanker te maken hebben, samen met twee afgevaardigden van de BorstkankerVereniging Nederland (BVN).

Methode ontwikkeling

Evidence based

Werkwijze

De antwoorden op de uitgangsvragen (daardoor de aanbevelingen in deze richtlijn) zijn voor zover mogelijk gebaseerd op gepubliceerd wetenschappelijk onderzoek. De geselecteerde artikelen zijn door de methodoloog beoordeeld op kwaliteit van het onderzoek en gegradeerd naar mate van bewijs, waarbij onderstaande indeling is gebruikt.

Indeling van onderzoeksresultaten naar mate van bewijskracht bij diagnostische tests

A1

onderzoek naar de effecten van diagnostiek op klinische uitkomsten bij een prospectief gevolgde goed gedefinieerde patiëntengroep met een tevoren gedefinieerd beleid op grond van de te onderzoeken testuitslagen, of besliskundig onderzoek naar de effecten van diagnostiek op klinische uitkomsten, waarbij resultaten van onderzoek van A2-niveau als basis worden gebruikt en voldoende rekening wordt gehouden met onderlinge afhankelijkheid van diagnostische testen.

A2

Onderzoek ten opzichte van een referentietest, waarbij van tevoren criteria zijn gedefinieerd voor de te onderzoeken test en voor een referentietest,  met een goede beschrijving van de test en de onderzochte klinische populatie; het moet een voldoende grote serie van opeenvolgende patiënten betreffen, er moet gebruik gemaakt zijn van tevoren gedefinieerde afkapwaarden en de resultaten van de test, en de ‘gouden standaard’ moeten onafhankelijk zijn beoordeeld. Bij situaties waarbij multiple, diagnostische testen een rol spelen, is er in principe een onderlinge afhankelijkheid en dient de analyse hierop te zijn aangepast, bijvoorbeeld met logistische regressie.

B

Vergelijking met een referentietest, beschrijving van de onderzochte test en van de onderzochte populatie, maar niet de kenmerken die verder onder niveau A staan genoemd.

C

Niet-vergelijkend onderzoek

D

Mening van deskundigen (bijvoorbeeld werkgroepleden).


Indeling van onderzoeksresultaten naar mate van bewijskracht bij interventiestudies

A1

Systematische reviews die ten minste enkele onderzoeken van A2-niveau betreffen, waarbij de resultaten van afzonderlijke onderzoeken consistent zijn.

A2

Gerandomiseerd vergelijkend klinisch onderzoek van goede kwaliteit en met voldoende omvang en consistentie.

B

Gerandomiseerde klinische trials van matige kwaliteit of onvoldoende omvang of ander vergelijkend onderzoek (niet-gerandomiseerd: vergelijkend cohortonderzoek, patiënt-controle-onderzoek).

C

Niet-vergelijkend onderzoek.

D

Mening van deskundigen (bijvoorbeeld de werkgroepleden).


Op basis van de literatuur worden per paragraaf één of meerdere relevante conclusies beschreven. De belangrijkste literatuur wordt naar mate van bewijs weergegeven, waardoor conclusies op basis van level of evidence geformuleerd kunnen worden. Alle literatuur die in de conclusie is opgenomen is beschreven in de literatuuromschrijving. 

Niveau van bewijskracht van de conclusie op basis van het ten grondslag liggend bewijs

Niveau van bewijs

Conclusie gebaseerd op

Formulering

1

1 systematische review (A1) of ten minste 2 onafhankelijk van elkaar uitgevoerde onderzoeken van niveau A1 of A2.

Het is aangetoond dat…; men dient…

2

Ten minste 2 onafhankelijk van elkaar uitgevoerde onderzoeken van niveau B.

Het is aannemelijk dat…; men zou…moeten…

3

1 onderzoek van niveau A2 of B, of ten minste 1 onderzoek van niveau C.

Er zijn aanwijzingen dat…; men kan…

4

Mening van deskundigen (bijvoorbeeld de werkgroepleden).

De werkgroep is van mening dat…


Op basis van de conclusie(s) worden aanbevelingen geformuleerd. Echter, naast de evidence uit de literatuur zijn er andere overwegingen die meespelen bij het formuleren van de aanbeveling, zoals veiligheid, patiëntperspectief, professioneel perspectief, kosteneffectiviteit, organisatie en maatschappij. De overige overwegingen worden telkens apart vermeld. Op deze manier wordt duidelijk hoe de werkgroep tot een bepaalde aanbeveling is gekomen. De uiteindelijk geformuleerde aanbeveling is het resultaat van de wetenschappelijke conclusie, waarbij de overige overwegingen in acht worden genomen. Door het richtlijnontwikkelproces op deze manier vorm te geven wordt de transparantie van de richtlijn verhoogd.

 

Actualisering/levende richtlijn

De richtlijn borstkanker is al vaak gereviseerd. Er wordt geen standaard termijn van revisie aangehouden. Het NABON bespreekt regelmatig welke knelpunten op het gebied van screening, diagnostiek, behandeling en nazorg in het veld leven en of de richtlijn daardoor op één of meerdere punten aangepast dient te worden. Zo is de in 2000 uitgebrachte richtlijn Screening en diagnostiek van het mammacarcinoom in 2007 gereviseerd. In 2002 is de eerste multidisciplinaire richtlijn voor de behandeling van het mammacarcinoom verschenen. De behandelrichtlijn is in 2004, 2005, 2006 en 2008 herzien. In 2008 zijn de screenings- en behandelingrichtlijn samengevoegd, welke in 2012 en 2017/2018 gereviseerd is.